Insider Selling: Annexon (NASDAQ:ANNX) EVP Sells $31,747.50 in Stock

Annexon, Inc. (NASDAQ:ANNX) EVP Michael Overdorf sold 6,225 shares of Annexon stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $5.10, for a total transaction of $31,747.50. Following the transaction, the executive vice president directly owned 124,464 shares of the company’s stock, valued at approximately $634,766.40. This trade represents a 4.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Annexon Stock Performance

Shares of ANNX opened at $4.90 on Monday. Annexon, Inc. has a fifty-two week low of $1.28 and a fifty-two week high of $7.18. The firm’s 50-day simple moving average is $5.58 and its two-hundred day simple moving average is $3.96. The stock has a market cap of $586.19 million, a PE ratio of -3.48 and a beta of 1.17.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Wells Fargo & Company lifted their price objective on Annexon from $14.00 to $27.00 and gave the company an “overweight” rating in a research note on Wednesday, November 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Annexon in a research report on Wednesday, January 21st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Annexon in a research note on Wednesday, January 14th. Finally, Chardan Capital began coverage on shares of Annexon in a research note on Tuesday, December 23rd. They set a “buy” rating and a $16.00 price objective for the company. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Adage Capital Partners GP L.L.C. increased its holdings in Annexon by 266.7% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 5,500,000 shares of the company’s stock worth $27,610,000 after buying an additional 4,000,000 shares in the last quarter. Mak Capital One LLC purchased a new stake in shares of Annexon during the 4th quarter valued at about $14,852,000. State Street Corp boosted its holdings in shares of Annexon by 126.9% during the 4th quarter. State Street Corp now owns 4,652,185 shares of the company’s stock valued at $23,354,000 after acquiring an additional 2,601,877 shares during the last quarter. Nuveen LLC grew its stake in shares of Annexon by 327.1% in the fourth quarter. Nuveen LLC now owns 2,915,324 shares of the company’s stock worth $14,635,000 after acquiring an additional 2,232,766 shares during the period. Finally, BVF Inc. IL raised its holdings in shares of Annexon by 30.4% during the fourth quarter. BVF Inc. IL now owns 9,128,080 shares of the company’s stock valued at $45,823,000 after purchasing an additional 2,128,080 shares during the last quarter.

Key Headlines Impacting Annexon

Here are the key news stories impacting Annexon this week:

• Neutral Sentiment: Short-interest reports for Feb. 19–20 show 0 shares of reported short interest and a 0.0 days-to-cover metric — this appears to be a data/reporting anomaly (NaN changes). The readings do not indicate meaningful new short activity to explain the move. Short Interest Report
• Negative Sentiment: EVP Michael Overdorf sold 6,225 shares at an average $5.10 (≈$31.7k); his holdings fell ~4.8%. Form 4 – Overdorf
• Negative Sentiment: EVP Ted Yednock sold 7,857 shares at an average $5.11 (≈$40.1k); his position dropped ~7.5%. Form 4 – Yednock
• Negative Sentiment: EVP Dean Richard Artis sold 5,290 shares at an average $5.10 (≈$27.0k); his holding decreased ~4.1%. Form 4 – Artis
• Negative Sentiment: CFO Jennifer Lew sold 7,851 shares at an average $5.11 (≈$40.1k); her stake fell ~6.5%. Form 4 – Lew
• Negative Sentiment: Insider Jamie Dananberg sold 5,290 shares at an average $5.10 (≈$27.0k); his holding declined ~6.7%. Form 4 – Dananberg

Annexon Company Profile

Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company’s research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.

At the core of Annexon’s pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.